



Attorney Docket No.: 5784.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Arne Staby

Confirmation No.: 6001

Application No.: 09/671,461

Group Art Unit: 1653

Filed: September 27, 2000

Examiner: Kam, Chih Min

For: Ion exchange chromatography of proteins and peptides

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material reference than the one listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The reference is as follows:

1. Kreyman et al (1988) FEBS Letters, Volume 242: pages 167-170.

11/02/2005 NNGUYEN1 00000021 141447 09671461

02 FC:1806 180.00 DA

Attorney Docket No.: 5784.210-US
Application Serial No.: 09/671,461
Filed: September 27, 2000
Inventor: Arne Staby
Express Mail Label No. : EV 246879127 US


It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached reference.

This supplemental information disclosure statement is being filed **after** the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this supplemental information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). The Examiner is authorized to charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: October 31, 2005


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650
PATENT TRADEMARK OFFICE

Serial No. 09/671,461

Applicant Arne Staby

Filing Date **September 27, 2000**

Group 1653

[illegible][illegible][illegible]

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.